



## (51) International Patent Classification:

A61K 35/15 (2015.01) C12Q 1/6881 (2018.01)

A61K 39/00 (2006.01)

## (21) International Application Number:

PCT/US2022/075362

## (22) International Filing Date:

23 August 2022 (23.08.2022)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

63/236,556 24 August 2021 (24.08.2021) US

(71) Applicants: **THE CHILDREN'S HOSPITAL OF PHILADELPHIA** [US/US]; 3401 Civic Center Blvd., Philadelphia, PA 19104 (US). **MYRIO THERAPEUTICS PTY LTD** [AU/AU]; Unit 1, 6-16 Joseph St., Blackburn North, 3130 (AU).

(72) Inventors: **BEASLEY, Matthew**; c/o Myrio Therapeutics Pty Ltd., Unit 1, 6-16 Joseph St., Blackburn North,

3130 (AU). **KIEFEL, Ben**; c/o Myrio Therapeutics Pty Ltd., Unit 1, 6-16 Joseph St., Blackburn North, 3130 (AU). **MARIS, John**; c/o The Children's Hospital of Philadelphia, 2716 South Street, 15th Floor, Philadelphia, PA 19146 (US). **YARMARKOVICH, Mark**; 1127 S. 48th Street, Apt. 3F, Philadelphia, PA 19143 (US). **GRACEY, Fiona**; c/o Myrio Therapeutics Pty Ltd., Unit 1, 6-16 Joseph St., Blackburn North, 3130 (AU). **SGOURAKIS, Nickolaos**; c/o The Children's Hospital of Philadelphia, 2716 South Street, 15th Floor, Philadelphia, PA 19146 (US). **WAR-RINGTON, John**; c/o The Children's Hospital of Philadelphia, 2716 South Street, 15th Floor, Philadelphia, PA 19146 (US). **MARSHALL, Quinlen**; c/o The Children's Hospital of Philadelphia, 2716 South Street, 15th Floor, Philadelphia, PA 19146 (US).

(74) Agent: **HIGHLANDER, Steven, L.**; Parker Highlander PLLC, 1120 S. Capital of Texas Highway, Building One, Suite 200, Austin, TX 78746 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

(54) Title: PEPTIDE-CENTRIC CHIMERIC ANTIGEN RECEPTORS TO CANCER SELF-PEPTIDES

| Parent gene | Peptide    | Relative Binding : PHOX2B | Normal Tissue Ligandome |
|-------------|------------|---------------------------|-------------------------|
| PHOX2B      | QYNPIRTTF  | 1.00                      | F                       |
| ABCA8       | MWQAIRATF  | 0.36                      | F                       |
| MYO7B       | RQSPWRIRYF | 0.30                      | F                       |
| FDFI1       | HYSPIYLSF  | 0.08                      | T                       |
| C6orf99     | RSTAIRQTF  | 0.04                      | F                       |
| MAPT3A      | QDAPLEPTF  | 0.01                      | F                       |
| NLRC5       | REAPIHLDF  | 0.01                      | F                       |
| KLHL1       | TQQPARTLF  | 0.01                      | F                       |
| CHRNA3      | IYPDITYSL  | 0.01                      | F                       |
| EFCAB6      | CWRPMRRRTF | 0.00                      | F                       |
| XPR1        | QPAPAWTTF  | 0.00                      | F                       |
| SLC23A2     | SYLPISPTF  | 0.00                      | T                       |
| TNS4        | VQKAISTTF  | 0.00                      | T                       |
| CGNL1       | YEAPVSYTF  | 0.00                      | F                       |
| SARS        | GYIFIYTPF  | 0.00                      | F                       |
| ATG16L1     | RTNAIKQTF  | 0.00                      | F                       |
| MX2         | LYNKIREDF  | 0.00                      | F                       |




FIG. 7

(57) Abstract: The neuroblastoma immunopeptidome is enriched with peptides derived from proteins essential for tumorigenesis including the unmutated peptide QYNPIRTTF (SEQ ID NO: 1) discovered on HLA-A\*24:02 which is derived from the neuroblastoma dependency gene and master transcriptional regulator PHOX2B. To target QYNPIRTTF, peptide-centric chimeric antigen receptors (PC-CARs) were developed via a counter panning strategy using predicted potentially cross-reactive peptides. Informed by computational modeling, PHOX2B peptide-centric CARs were demonstrated to also recognize QYNPIRTTF (SEQ ID NO: 1) presented by HLA-A\*23:01 and the highly divergent HLA-B\*14:02. Potent and specific killing of neuroblastoma cells expressing these HEAs in vitro was shown along with complete tumor regression in mice.

[Continued on next page]

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

- (84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

**(88) Date of publication of the international search report:**

13 April 2023 (13.04.2023)